Cytomos Showcases AuraCyt Cell Analytics Platform

The Cytomos AuraCyt® platform unlocks the power of predictive cell intelligence, by measuring intrinsic cell physics to generate AI-ready digital fingerprints that reveal the true multi-dimensional state and behaviour of the cell.

The showcase benchtop cell analytics intelligence system combines the compact Celledonia® analyser with the precision silicon sensors of the AuraCyt® modules, powering the AuraCyt® Analysis Suite to transform complex cellular data into actionable insights.

This rapid, label-free, single-cell analysis system predicts future productivity, stability and manufacturability, enabling earlier insights and real- time decision-making, lowering risk, providing scalable impact, optimising process and improving product consistency.

This provides demonstrable value across various applications, such as reducing CLD timelines by up to 40%, saving up to 65% of resources in lentivirus batch production, and reducing CAR-T process time by up to 30%. Cytomos is showcasing this novel technology at its pod in BIO Business Forum Zone D (Exhibit Hall 2221 UK Pavillion), from 22-25 th of June, 2026. BIO International is the world’s largest biotechnology gathering, bringing together thousands of leaders across the global life sciences community from academia, industry, and finance to showcase breakthrough technologies.

Cytomos continues to engage with strategic partners to integrate their revolutionary technology into existing workflows, helping accelerate drug discovery, drug development, and scale-up across multiple biomanufacturing arenas. Cytomos also offers innovation with Celledonia® powered by AuraCyt® uniquely predicts cell behaviour by capturing a digital fingerprint of every cell - delivering rapid, high- resolution insights into cell health, phenotype, and function. quality by design – highlighted by the recent ISO 9001 certification of Cytomos with zero non-conformances, reinforcing Cytomos as a trusted partner in the life sciences sector. 

Cytomos Executive Chair, Alan Raymond commented, “Our customers, partners and investors can be confident that Cytomos operates to the highest international standards,” and continued “This is not just a badge – it’s a reflection of our mission to deliver reliable, reproducible, and meaningful results in cell analysis. Integrating our ground-breaking Auracyt® platform into existing workflows will transform bioprocessing and manufacturing, by detecting cell features for which there are no current biomarkers and providing predictive insights into how those cells will behave during processing. In short, it lets you see what's coming - before it happens.”

To achieve this, Cytomos works closely alongside partners to integrate their pioneering technology into existing processes via a dedicated team of scientists and data analysts, who collaborate closely with multiple teams to make the AuraCyt® cell analytic intelligence systems both accessible and impactful.

This article has been republished from external sources. Note: Material may have been edited for clarity, length, or style. For more information, please contact the cited source.